Core Insights - Predictive Oncology Inc. has appointed Shawn Matthews, Thomas McLaughlin, and Sara Turken to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token [1][2][3] Leadership Appointments - Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, joins the Board of Directors [2][3] - Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., is appointed as Chief Investment Officer [2][4] - Sara Turken, JD, a biopharmaceutical veteran, is appointed as General Counsel [2][5] Strategic Focus - The company is leveraging its AI-driven drug discovery capabilities to implement an innovative digital treasury asset strategy, which aims to address its AI requirements and capitalize on the growing global need for AI infrastructure [3][8] - Predictive Oncology operates a digital asset treasury focused on the Aethir (ATH) token, creating the world's first Strategic Compute Reserve [8] Company Background - Predictive Oncology utilizes AI and machine learning to expedite early drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [6][7] - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [7]

Core Insights - Predictive Oncology has successfully closed two private investment in public equity transactions (PIPEs) totaling approximately $343.5 million to support its digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem [1][2] Investment Details - The PIPEs consist of two components: - A cash PIPE raising approximately $50.8 million through the sale of about 4.4 million shares of common stock at a price of $11.6265 per share [2] - A crypto PIPE involving pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per warrant, in exchange for approximately $292.7 million in notional value of ATH contributions [2] - The PIPEs closed on October 7, 2025, and the pre-funded warrants will be exercisable following shareholder approval [2][4] Strategic Intent - The company aims to utilize the in-kind contribution of ATH to fund its digital asset treasury strategy and acquire ATH in the open market, alongside working capital and general corporate purposes [4] - The investment aligns with the company's computational needs and capital requirements as it seeks to lead in AI-driven drug discovery [5] Company Background - Predictive Oncology leverages AI and machine learning for drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [9] - The company has a biobank of over 150,000 tumor samples, enhancing its AI-based drug discovery capabilities [9] Aethir Overview - Aethir is a decentralized physical infrastructure network providing GPU resources for AI computation, gaming, and cloud workloads, aiming to democratize access to AI infrastructure [7][8] - ATH serves as a utility token within the Aethir ecosystem, facilitating GPU rentals, staking, and rewards [8]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining around 150 points on Monday, while the Dow rose 0.19% to 46,333.68, the NASDAQ increased 0.67% to 22,635.76, and the S&P 500 climbed 0.42% to 6,671.51 [1] - Information technology shares jumped by 0.8%, while energy stocks fell by 0.8% [1] Real Estate Sector - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [2][7] Commodity Market - Oil traded down 2% to $64.41, while gold increased by 0.9% to $3,844.30. Silver rose 0.5% to $46.895, and copper gained 0.7% to $4.8070 [4] European Market - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%, while Spain's IBEX 35 Index fell 0.2%. London's FTSE 100 rose 0.4%, Germany's DAX 40 slipped 0.1%, and France's CAC 40 climbed 0.3% [5] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng gaining 1.89%, China's Shanghai Composite rising 0.90%, and India's BSE Sensex falling 0.08% [6] Stock Performance - Maison Solutions Inc. (NASDAQ: MSS) shares surged 257% to $3.3603, while Predictive Oncology Inc. (NASDAQ: POAI) increased 112% to $1.64 after announcing a 1-for-15 reverse stock split. Maison Solutions Inc. also saw a 167% gain to $2.56 [9] - KALA BIO, Inc. (NASDAQ: KALA) shares dropped 92% to $1.4350 after failing to meet primary endpoints in a clinical trial. MoonLake Immunotherapeutics (NASDAQ: MLTX) shares fell 89% to $6.76 following disappointing trial results, and IO Biotech, Inc. (NASDAQ: IOBT) was down 75% to $0.3941 after an update post-FDA meeting [9]

Core Viewpoint - Predictive Oncology is advancing its artificial intelligence and machine learning initiatives to enhance early drug discovery and drug development for cancer patients globally, while also implementing a digital asset treasury strategy involving ATH tokens from the Aethir ecosystem [1][14]. Transaction Overview - The company plans to raise approximately $344.4 million through two private investment transactions, which include the sale of about 66.7 million shares at a price of $0.7751 per share, generating around $51.7 million in cash proceeds, and pre-funded warrants for up to 223.6 million shares, valued at approximately $292.7 million in notional value [2]. - The transactions are expected to close around October 2, 2025, pending customary closing conditions [2]. Use of Proceeds - The funds from the private placements will primarily be used to support the digital asset treasury strategy, acquire ATH tokens in the open market, and for general corporate purposes [3]. Aethir Infrastructure - Aethir operates a large decentralized GPU network, providing AI infrastructure with cost savings of approximately 40-80% compared to traditional providers, and offers rapid deployment of services [4]. - The network consists of 435,000 GPU containers across over 200 locations in 93 countries, facilitating global access to Nvidia GPUs-as-a-Service [4]. Digital Asset Strategy - The digital asset treasury will manage ATH tokens, leveraging Aethir's model to enhance the deployment and monetization of compute resources across various enterprise sectors [5]. - For every ATH token purchased, the DCI Foundation will grant an additional 20% of the tokens to the company, linking ATH token value to real-world infrastructure demand [6]. Strategic Partnership - The partnership with Aethir is viewed as a significant opportunity for Predictive Oncology to solidify its core business and explore growth through the digital asset treasury strategy [7]. - The company aims to establish the world's first Strategic Compute Reserve, functioning as an operator within the Aethir ecosystem [8]. Advisory and Legal Support - DNA Holdings Venture, Inc. is acting as the strategic advisor for the digital asset treasury, while H.C. Wainwright & Co. serves as the exclusive placement agent for the private placements [9].

Core Viewpoint - Predictive Oncology Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective September 30, 2025 [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 15 shares of common stock into one share, resulting in a reduction from 11,436,201 shares outstanding to approximately 762,414 shares [3][4]. - The reverse stock split will not change the par value per share and will affect all stockholders uniformly, with fractional shares being rounded up to the nearest whole share [3][4]. - Stockholders will receive a transaction statement from Pacific Stock Transfer, the exchange agent, detailing their new share count post-split [3][4]. Group 2: Company Overview - Predictive Oncology is focused on AI-driven drug development, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, enhancing its drug discovery capabilities [5]. - Predictive Oncology is headquartered in Pittsburgh, PA, and aims to expedite drug development for cancer patients globally [5].

Core Insights - Predictive Oncology Inc. and Every Cure have announced a strategic collaboration aimed at identifying and prioritizing existing drugs for repurposing to enhance patient outcomes and save lives [1][4] - The collaboration leverages AI-driven platforms and extensive biobanks to accelerate drug repurposing efforts, particularly for patients with cancer and other diseases lacking approved treatments [3][8] Group 1: Company Overview - Predictive Oncology is a leader in AI-driven drug development, utilizing machine learning to predict patient responses to anti-cancer therapies [2][8] - The company has a biobank of over 150,000 tumor samples across more than 130 cancer types, which supports its drug discovery and development processes [5][8] - Every Cure is a nonprofit organization focused on repurposing existing drugs to treat diseases, aiming to deliver treatments quickly and cost-effectively [3][6] Group 2: Collaboration Details - The partnership aims to combine the AI capabilities of both organizations to overcome barriers in drug repurposing and improve healthcare accessibility [4][5] - Every Cure's AI models utilize knowledge graphs and real-world medical data to identify potential drug-disease connections, which are then evaluated for safety and efficacy [5] - Predictive Oncology's platform has demonstrated a 92% accuracy in predicting tumor responses to drugs, enhancing the selection process for drug testing [8]

Group 1 - The proposed sale of Predictive Oncology Inc. to Renovaro Inc. involves a merger where Predictive Oncology shareholders will receive a newly created series of preferred stock in a 1:1 exchange for their existing common stock [1] - Kahn Swick & Foti, LLC is investigating whether the terms of the proposed sale adequately reflect the value of Predictive Oncology and the process leading to this transaction [1] - The investigation is led by former Louisiana Attorney General Charles C. Foti, Jr., indicating a legal scrutiny of the transaction [1][2] Group 2 - Kahn Swick & Foti, LLC is open to discussions regarding the legal rights of shareholders who believe the transaction undervalues Predictive Oncology [2] - Shareholders can contact KSF Managing Partner Lewis S. Kahn for more information about their rights related to the proposed sale [2]

Financial Performance - The company reported a loss from continuing operations of approximately $2.0 million for Q2 2025, compared to a loss of $2.5 million in Q2 2024[1][10]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to decreased sales of tumor-specific 3D models and kits[8][11]. - Basic and diluted loss per common share from continuing operations was $0.22 for Q2 2025, down from $0.53 in Q2 2024[8][11]. - Total stockholders' deficit increased to $1,653,400 as of June 30, 2025, compared to a deficit of $202,610 as of December 31, 2024[8][9]. Cash and Expenses - The company ended Q2 2025 with $506,078 in cash and cash equivalents, down from $611,822 as of December 31, 2024[8][9]. - General and administrative expenses increased by $50,481 to $1,875,655 in Q2 2025, compared to $1,825,174 in Q2 2024[8][11]. Market Expansion and Product Development - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both anticipated in Q4 2025[3][4]. - The company has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity[4]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications[4]. Financing Activities - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP[4].

Core Viewpoint - Predictive Oncology reported a loss from continuing operations of approximately $2.0 million for Q2 2025, while focusing on advancing its AI-driven drug discovery and expanding its ChemoFx assay in the U.S. and Europe [1][3]. Financial Summary - The company concluded Q2 2025 with cash and cash equivalents of $506,078, down from $611,822 as of December 31, 2024 [4]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to reduced sales of tumor-specific 3D models and kits [10]. - General and administrative expenses increased to $1,875,655 in Q2 2025 from $1,825,174 in Q2 2024, mainly due to higher legal fees [10]. - The company raised approximately $586,000 in gross proceeds during the quarter through private placements and its At-the-Market facility [6]. Operational Highlights - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both expected in Q4 2025 [5]. - ChemoFx helps oncologists make better treatment decisions by testing multiple chemotherapies on patients' cancer cells before treatment selection [5]. - Predictive Oncology has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity [5]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications [5]. Capital and Investment - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP, providing a flexible source of capital for advancing initiatives [5].

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its ...